Literature DB >> 15834282

Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats.

Céline Demougeot1, Anne Prigent-Tessier, Christine Marie, Alain Berthelot.   

Abstract

OBJECTIVE: A decrease in nitric oxide (NO) bioavailability has been proposed to contribute to endothelial dysfunction and increased peripheral resistances during essential arterial hypertension. Given that arginine is a substrate for both arginase and NO synthase, arginase activity may be a critical factor in NO bioavailability. To test this hypothesis, we evaluated the effects of the arginase inhibitor alpha-difluoromethylornithine (DFMO) in spontaneously hypertensive rats (SHR).
METHODS: Vascular reactivity experiments were performed on thoracic aortic rings from 10-week-old SHR and their normotensive counterparts, Wistar-Kyoto (WKY) rats. Blood pressure was measured by the tail-cuff method. DFMO treatment (30 mg/kg daily in drinking water) was started in 5-week-old SHR and maintained for 5 weeks. Aortic arginase I and arginase II expression as well as arginase activity were evaluated by western blotting and the spectrophotometric method, respectively.
RESULTS: DFMO (1.2 x 10 mol/l) enhanced the vascular response to acetylcholine both in SHR (+24%, P < 0.01) and WKY rats (+12%, P < 0.01), and reversed the effects of the NO synthase inhibitor N-nitro-L-arginine-methyl-ester. The vasorelaxant response to sodium nitroprusside on endothelium-denuded rings was not affected by DFMO, neither in SHR nor in WKY rats. In SHR, DFMO prevented the increase in blood pressure and improved the response of aortic rings to acetylcholine. Finally, as compared with WKY rats, SHR exhibited increased expression of vascular arginase I (+72%, P < 0.05) and arginase II (+91%, P < 0.05) as well as increased arginase activity (+26%, P < 0.05).
CONCLUSIONS: Our results showed that arginase inhibition reduced endothelial dysfunction and blood pressure rising in SHR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834282     DOI: 10.1097/01.hjh.0000166837.78559.93

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  49 in total

1.  Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

Review 2.  Endothelial arginase: a new target in atherosclerosis.

Authors:  Zhihong Yang; Xiu-Fen Ming
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

3.  Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.

Authors:  Alia Shatanawi; Maritza J Romero; Jennifer A Iddings; Surabhi Chandra; Nagavedi S Umapathy; Alexander D Verin; Ruth B Caldwell; R William Caldwell
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

Review 4.  Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Authors:  William Durante; Fruzsina K Johnson; Robert A Johnson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

Review 5.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

6.  Upregulation of arginase activity contributes to intracellular ROS production induced by high glucose in H9c2 cells.

Authors:  Lu Zhou; Chuan-Bo Sun; Chao Liu; Yue Fan; Hong-Yi Zhu; Xiao-Wei Wu; Liang Hu; Qing-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 7.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

8.  Arginase II deletion increases corpora cavernosa relaxation in diabetic mice.

Authors:  Haroldo A Toque; Rita C Tostes; Lin Yao; Zhimin Xu; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2010-11-03       Impact factor: 3.802

9.  Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism.

Authors:  Jochen Steppan; Sungwoo Ryoo; Karl H Schuleri; Chris Gregg; Rani K Hasan; A Ron White; Lukasz J Bugaj; Mehnaz Khan; Lakshmi Santhanam; Daniel Nyhan; Artin A Shoukas; Joshua M Hare; Dan E Berkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets.

Authors:  Aaron Erdely; Diane Kepka-Lenhart; Rebecca Salmen-Muniz; Rebecca Chapman; Tracy Hulderman; Michael Kashon; Petia P Simeonova; Sidney M Morris
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.